SPI Medical Imaging: MASAI Results Challenge the Double Standard

AI was one of the hottest topics at this year’s European Congress of Radiology (ECR), with the latest results from ScreenPoint Medical’s MASAI trial covered in one of the many interesting talks at the AI theatre.

Interim results from the trial, which was designed to evaluate the clinical safety and efficacy of AI-assisted single mammography reader breast cancer screening compared to standard double reading, were published in August 2023.

At that time, ScreenPoint’s Transpara breast AI solution was shown to be potentially beneficial for screening programmes, however with AI-supported mammography screening resulting in a similar cancer detection rate compared with standard double reading, rather than providing a significant advantage, the results were not compelling enough to sway opinions in favour of changing the double reader standard in Europe. However, the latest results may paint a different picture.